An Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCs

An Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCs

Stem cells are classified into embryonic stem cells and adult stem cells. An evolving alternative to conventional stem cell therapies is induced pluripotent stem cells (iPSCs), which have a multi-lineage potential comparable to conventionally acquired embryonic stem cells with the additional benefit...

Full description

Bibliographic Details
Main Authors: Menon, Siddharth, Shailendra, Siny, Renda, Andrea, Longaker, Michael, Quarto, Natalina
Format: Online
Language:English
Published: MDPI 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4730380/
id pubmed-4730380
recordtype oai_dc
spelling pubmed-47303802016-02-11 An Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCs Menon, Siddharth Shailendra, Siny Renda, Andrea Longaker, Michael Quarto, Natalina Review Stem cells are classified into embryonic stem cells and adult stem cells. An evolving alternative to conventional stem cell therapies is induced pluripotent stem cells (iPSCs), which have a multi-lineage potential comparable to conventionally acquired embryonic stem cells with the additional benefits of being less immunoreactive and avoiding many of the ethical concerns raised with the use of embryonic material. The ability to generate iPSCs from somatic cells provides tremendous promise for regenerative medicine. The breakthrough of iPSCs has raised the possibility that patient-specific iPSCs can provide autologous cells for cell therapy without the concern for immune rejection. iPSCs are also relevant tools for modeling human diseases and drugs screening. However, there are still several hurdles to overcome before iPSCs can be used for translational purposes. Here, we review the recent advances in somatic reprogramming and the challenges that must be overcome to move this strategy closer to clinical application. MDPI 2016-01-21 /pmc/articles/PMC4730380/ /pubmed/26805822 http://dx.doi.org/10.3390/ijms17010141 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Menon, Siddharth
Shailendra, Siny
Renda, Andrea
Longaker, Michael
Quarto, Natalina
spellingShingle Menon, Siddharth
Shailendra, Siny
Renda, Andrea
Longaker, Michael
Quarto, Natalina
An Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCs
author_facet Menon, Siddharth
Shailendra, Siny
Renda, Andrea
Longaker, Michael
Quarto, Natalina
author_sort Menon, Siddharth
title An Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCs
title_short An Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCs
title_full An Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCs
title_fullStr An Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCs
title_full_unstemmed An Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCs
title_sort overview of direct somatic reprogramming: the ins and outs of ipscs
description Stem cells are classified into embryonic stem cells and adult stem cells. An evolving alternative to conventional stem cell therapies is induced pluripotent stem cells (iPSCs), which have a multi-lineage potential comparable to conventionally acquired embryonic stem cells with the additional benefits of being less immunoreactive and avoiding many of the ethical concerns raised with the use of embryonic material. The ability to generate iPSCs from somatic cells provides tremendous promise for regenerative medicine. The breakthrough of iPSCs has raised the possibility that patient-specific iPSCs can provide autologous cells for cell therapy without the concern for immune rejection. iPSCs are also relevant tools for modeling human diseases and drugs screening. However, there are still several hurdles to overcome before iPSCs can be used for translational purposes. Here, we review the recent advances in somatic reprogramming and the challenges that must be overcome to move this strategy closer to clinical application.
publisher MDPI
publishDate 2016
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4730380/
_version_ 1613529687309418496

Similar Items